TrialDiabetes care2022

Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial.

Yumie Takeshita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.